Drug Trial Radar · NCT06255028
A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases
Last checked: Nov 20, 2026Latest source record: Jan 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
6
Actual
Start
Feb 6, 2025
Primary completion
Aug 2028
Study completion Aug 2028
Sponsor
- Lead sponsor
- Century Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
CALiPSO-1 is a Phase 1, multi-centre, dose-confirmation study to evaluate the safety and efficacy of CNTY-101 in participants with refractory B cell-mediated autoimmune diseases including those with moderate to severe systemic lupus erythematosus (SLE) with or without lupus nephritis (LN), idiopathic inflammatory myopathies (IIM), and diffuse cutaneous systemic sclerosis (DcSSc).
Conditions
- Systemic Lupus Erythematosus
- Lupus Nephritis
- Idiopathic Inflammatory Myopathies
- Diffuse Cutaneous Systemic Sclerosis
Interventions
CNTY-101Biological
CNTY-101 cells for intravenous (IV) infusion
IL-2Biological
IL-2 subcutaneous (SC) injection
Lymphodepleting ChemotherapyDrug
LDC as prespecified in the protocol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) and Severity of TEAEsTime frame: Up to 29 days
- Percentage of Participants With Dose Limiting Toxicities (DLTs)Time frame: Up to 28 days after first CNTY-101 infusion
- Recommended Phase 2 Regimen (RP2R) of CNTY-101 With/Without IL-2 (With or Without Optimized LDC)Time frame: Up to 3 months after the first CNTY-101 infusion
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Keck School of Medicine of University of Southern California
Los Angeles, California
UC Davis
Sacramento, California
Lurie Children's; Northwestern Medicine - Northwestern Medical Group
Chicago, Illinois
Texas Children's Hospital
Houston, Texas
Primary Children's Hospital
Salt Lake City, Utah
Fred Hutch
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.